Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592111 · ClinicalTrials.gov registry record · Phase 2
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
A Phase 2 study of Hodgkin's Disease and Pediatric, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00592111 is a Phase 2 study of Hodgkin's Disease and Pediatric that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21 participants, below the 237-participant average among 20 other Hodgkin's Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00592111, a Phase 2 study of Hodgkin's Disease and Pediatric, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.
Conditions Studied
Interventions
- DRUG COPP/ABV
- DRUG intensive chemo with concurrent growth factor
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 1996-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592111
The ClinicalTrials.gov registry entry for NCT00592111 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 20 other Hodgkin's Disease trials with a reported enrollment target (91% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hodgkin's Disease appearing as the primary indexed condition, and to 2 interventions - of which COPP/ABV is the first listed.
NCT00592111 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00592111 about?
NCT00592111 is a clinical study titled "A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)". Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.
What is the current status of trial NCT00592111?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 1996-03. Estimated completion is 2008-01.
What conditions does trial NCT00592111 study?
This clinical trial studies the following conditions: Hodgkin's Disease, Pediatric.
What interventions are being tested in trial NCT00592111?
The interventions under investigation include: COPP/ABV (DRUG), intensive chemo with concurrent growth factor (DRUG).
Who is sponsoring clinical trial NCT00592111?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00592111 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
COMPLETED · Phase 2
-
Amifostine for Head and Neck Irradiation in Lymphoma
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
COMPLETED · Phase 2
-
Mantle Irradiation for Hodgkin's Disease
COMPLETED · Phase 2
-
Allogeneic Transplantation From Related Haploidentical Donors
COMPLETED · Phase 2
-
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.